I am an investor

I want to know more about Cantargia's research

I want to know more about Cantargia as a company

CEO presentation

To the presentation (in Swedish)

Presentation at ASCO 2019, follow up articles and interviews

Cantargia interview at EFN after ASCO

To the interview (in Swedish)

Cantargia partners up with pioneer within biotech industry

A brief introduction to Cantargia

To the interview

Press releases

2020-12-30 (R) New number of shares and votes in Cantargia

2020-12-21 (R) Changes to Cantargia’s nomination committee

2020-12-16 (R) Cantargia has completed a directed share issue of approximately SEK 564 million

(R) = Regulatory press releases

”During 2018, we concluded the first very important part of the clinical development of CAN04 and presented patient data that strengthens our hopes that CAN04 can become an important part of tomorrow’s cancer treatment”

Göran Forsberg

CEO Cantargia

Analysis

2020-10-13, Nordea analysis of Cantargia

2020-10-30, Edison analysis of Cantargia

2020-10-14, Nordea analysis of Cantargia

2020-10-09, Redeye analysis of Cantargia (in Swedish)

Presentations